108 related articles for article (PubMed ID: 24987911)
1. In vitro chemoresponse analysis of cervical cancer patient specimens.
Grigsby PW; Gan CM; Tillmanns TD; Del Priore G
Int J Gynecol Cancer; 2014 Nov; 24(9):1665-74. PubMed ID: 24987911
[TBL] [Abstract][Full Text] [Related]
2. In vitro chemoresponse to cisplatin and outcomes in cervical cancer.
Grigsby PW; Zighelboim I; Powell MA; Mutch DG; Schwarz JK
Gynecol Oncol; 2013 Jul; 130(1):188-91. PubMed ID: 23583416
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
[TBL] [Abstract][Full Text] [Related]
4. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy.
Mabuchi S; Morishige K; Fujita M; Tsutsui T; Sakata M; Enomoto T; Kimura T
Gynecol Oncol; 2009 May; 113(2):200-4. PubMed ID: 19268342
[TBL] [Abstract][Full Text] [Related]
5. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.
Kitagawa R; Katsumata N; Ando M; Shimizu C; Fujiwara Y; Yoshikawa H; Satoh T; Nakanishi T; Ushijima K; Kamura T
Gynecol Oncol; 2012 May; 125(2):307-11. PubMed ID: 22333993
[TBL] [Abstract][Full Text] [Related]
6. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
Moore KN; Herzog TJ; Lewin S; Giuntoli RL; Armstrong DK; Rocconi RP; Spannuth WA; Gold MA
Gynecol Oncol; 2007 May; 105(2):299-303. PubMed ID: 17303230
[TBL] [Abstract][Full Text] [Related]
7. In vitro chemoresponse in metachronous pairs of gyneclologic cancers.
Dalton HJ; Fiorica J; McClure CK; Rocconi RP; Recio FO; Levocchio JL; Burrell MO; Monk BJ
Gynecol Oncol Res Pract; 2014; 1():7. PubMed ID: 27231560
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
Karageorgopoulou S; Kostakis ID; Gazouli M; Markaki S; Papadimitriou M; Bournakis E; Dimopoulos MA; Papadimitriou CA
BMC Cancer; 2017 Jun; 17(1):451. PubMed ID: 28659181
[TBL] [Abstract][Full Text] [Related]
9. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.
Hisamatsu T; Mabuchi S; Yoshino K; Fujita M; Enomoto T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2012 May; 22(4):623-9. PubMed ID: 22343974
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial.
Downs LS; Chura JC; Argenta PA; Judson PL; Ghebre R; Geller MA; Carson LF
Gynecol Oncol; 2011 Feb; 120(2):265-9. PubMed ID: 21145100
[TBL] [Abstract][Full Text] [Related]
11. First-line paclitaxel and carboplatin in persistent/recurrent or advanced cervical cancer: a retrospective analysis of patients treated at Brazilian National Cancer Institute.
Garces ÁH; Mora PA; Alves FV; do Carmo CC; Grazziotin R; Fernandes AC; Nogueira-Rodrigues A; de Melo AC
Int J Gynecol Cancer; 2013 May; 23(4):743-8. PubMed ID: 23552805
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.
Tiersten AD; Selleck MJ; Hershman DL; Smith D; Resnik EE; Troxel AB; Brafman LB; Shriberg L
Gynecol Oncol; 2004 Feb; 92(2):635-8. PubMed ID: 14766258
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
[TBL] [Abstract][Full Text] [Related]
15. Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer.
Lorusso D; Mainenti S; Pietragalla A; Fusco E; Malaguti P; Masciullo V; Scambia G
Oncology; 2011; 80(5-6):390-4. PubMed ID: 21829040
[TBL] [Abstract][Full Text] [Related]
16. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
[TBL] [Abstract][Full Text] [Related]
17. Consistency of in vitro chemoresponse assay results and population clinical response rates among women with endometrial carcinoma.
Huh WK; Cibull M; Gallion HH; Gan CM; Richard S; Cohn DE
Int J Gynecol Cancer; 2011 Apr; 21(3):494-9. PubMed ID: 21430456
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
Kitagawa R; Katsumata N; Shibata T; Kamura T; Kasamatsu T; Nakanishi T; Nishimura S; Ushijima K; Takano M; Satoh T; Yoshikawa H
J Clin Oncol; 2015 Jul; 33(19):2129-35. PubMed ID: 25732161
[TBL] [Abstract][Full Text] [Related]
19. [Neoadjuvant chemotherapy with paclitaxel and cisplantin or carboplatin for patients with locally advanced uterine cervical cancer].
Zhang R; Li B; Bai P; Li HJ; Li SM; Wu LY; Li W
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):616-20. PubMed ID: 22325224
[TBL] [Abstract][Full Text] [Related]
20. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Khawandanah M; Baxley A; Pant S
J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
